CAJ | 학술논문

目的：观察重组人脑利钠肽（新活素）治疗急性心力衰竭患者的临床疗效。方法入选住院急性心力衰竭患者122例，随机分为治疗组（n=60）和对照组（n=62），对照组给予标准基础治疗。治疗组加用新活素，比较2组临床疗效、一般指标和心功能指标的变化。结果治疗组心功能明显好转，左室射血分数上升，左室舒张末容积减少，血浆脑钠肽的浓度下降（P＜0.05）。结论新活素作为新型扩血管药物，可明显缓解症状，改善近期心功能状态。
목적：관찰중조인뇌리납태（신활소）치료급성심력쇠갈환자적림상료효。방법입선주원급성심력쇠갈환자122례，수궤분위치료조（n=60）화대조조（n=62），대조조급여표준기출치료。치료조가용신활소，비교2조림상료효、일반지표화심공능지표적변화。결과치료조심공능명현호전，좌실사혈분수상승，좌실서장말용적감소，혈장뇌납태적농도하강（P＜0.05）。결론신활소작위신형확혈관약물，가명현완해증상，개선근기심공능상태。
Objective To explore the effects of recombinant human brain natriuretic peptide on heart function in patients with acute heart failure. Methods 122 hospitalized patients with acute heart failure were selected, randomly divided into Xinhuosu group (n=60) and control group (n=62). Clinical efficacy, general index and the index of heart function of two groups were compared. Results The heart function of Xinhuosu group significantly improved, with left ventricular ejection fraction increased, left ventricular end diastolic volume reduced. The concentration of plasma brain natriuretic peptide of Xinhuosu group decreased (P<0.05). Conclusion As a new vasodilator, Xinhuosu can obviously alleviate the symptoms and improve cardiac function in patients with acute heart failure.